Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tizanidine
Drug ID BADD_D02230
Description Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Indications and Usage For the management of increased muscle tone associated with spasticity
Marketing Status Prescription; Discontinued
ATC Code M03BX02
DrugBank ID DB00697
KEGG ID D08611
MeSH ID C023754
PubChem ID 5487
TTD Drug ID D01MDT
NDC Product Code 50090-0840; 63629-8533; 61919-221; 68084-775; 63187-673; 43063-455; 50090-0813; 63629-7037; 60505-0251; 68788-9497; 67296-1599; 67296-1567; 70771-1335; 63629-3209; 71335-0737; 50090-0841; 16714-172; 55154-7287; 70934-811; 71610-455; 60760-694; 71610-228; 71610-451; 53002-1418; 63187-009; 50090-2078; 71335-1016; 70518-1598; 50090-0811; 57664-502; 71610-167; 71205-311; 60760-719; 71335-1799; 70518-0573; 68788-7782; 63629-1673; 70518-0133; 50090-5767; 68788-7991; 57664-503; 42291-809; 55111-179; 70771-1336; 60505-0252; 70518-1439; 60760-505; 63187-145; 0904-6418; 43353-167; 29300-168; 0615-8360; 68071-3288; 0904-6898; 71335-0424; 63187-493; 68071-5268; 42291-808; 63629-6432; 68788-9514; 72578-096; 68788-7781; 43063-868; 0615-8274; 70934-268; 71610-345; 50090-2208; 71610-162; 68071-4463; 16714-171; 55111-180; 63187-910; 50268-759; 70518-2210; 67296-1192; 35356-662; 29300-169; 68084-645; 70518-3112; 60760-253; 70518-3181; 60760-782; 68788-6365; 67296-1417; 50436-1180; 67877-614; 60760-263; 71335-0003; 72578-097; 63629-2370; 71335-0914; 50268-760; 68788-6444; 67877-613; 63629-2371; 71610-355
Synonyms tizanidine | 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole | Zanaflex | tizanidine hydrochloride | tizanidine monohydrochloride | DS 103-282 | Sirdalud
Chemical Information
Molecular Formula C9H8ClN5S
CAS Registry Number 51322-75-9
SMILES C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hallucination, auditory19.10.02.0030.000259%Not Available
Hallucination, visual19.10.02.0040.000259%Not Available
Headache17.14.01.0010.000517%
Hemiplegia17.01.04.002--Not Available
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic failure09.01.03.002--
Hepatic fibrosis24.08.06.002; 09.01.04.002--Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hepatic necrosis09.01.07.002--
Hepatitis09.01.07.004--Not Available
Hepatitis fulminant11.07.01.003; 09.01.07.007--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatotoxicity09.01.07.009; 12.03.01.008--Not Available
Herpes simplex23.09.03.001; 11.05.02.001--Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.0280.000388%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.000259%
Hypertonia15.05.04.007; 17.05.02.001--Not Available
Hypoaesthesia17.02.06.0230.000388%Not Available
Hypokalaemia14.05.03.002--
Hyponatraemia14.05.04.002--
Hypoproteinaemia14.10.01.003; 09.01.02.004--Not Available
Hypotension24.06.03.0020.002457%
Hypothyroidism14.11.01.012; 05.02.03.001--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages